Title: Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis:
post-marketing surveillance study
Version: 1 Date: 04 Apr 2024
Reviewer's report:
Thank you for submitting your paper.
I have questions regarding the following points, please answer them.
##JAK inhibitors are indicated and positioned for ulcerative colitis in intractable cases in which
at least one biological drug is ineffective or insufficiently effective.  In this cohort, bionaive
cases account for the majority, but are the indications and positioning of JAK inhibitors different
from international standards in South Korea? If so, please also mention the reason.
##Is there a difference in the incidence of adverse events between elderly and young people?
##Are the safety profiles and efficacy different for maintenance doses of 10 mg BID and 5 mg
BID? If the dose was changed and remission was maintained, would adverse events increase
with longer duration of 10 mg BID administration?
##Regarding herpes zoster risk management, how many patients received vaccinations? Did
the risk of developing HZ be reduced by whether or not vaccination was administered?
Title: Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis:
post-marketing surveillance study
Version: 1 Date: 04 Apr 2024
Reviewer's report:
Thank you for submitting your paper.
I have questions regarding the following points, please answer them.
##JAK inhibitors are indicated and positioned for ulcerative colitis in intractable cases in which
at least one biological drug is ineffective or insufficiently effective.  In this cohort, bionaive
cases account for the majority, but are the indications and positioning of JAK inhibitors different
from international standards in South Korea? If so, please also mention the reason.
##Is there a difference in the incidence of adverse events between elderly and young people?
##Are the safety profiles and efficacy different for maintenance doses of 10 mg BID and 5 mg
BID? If the dose was changed and remission was maintained, would adverse events increase
with longer duration of 10 mg BID administration?
##Regarding herpes zoster risk management, how many patients received vaccinations? Did
the risk of developing HZ be reduced by whether or not vaccination was administered?
Please review this paper.
user
Title: Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis:
post-marketing surveillance study
Version: 1 Date: 04 Apr 2024
Reviewer's report:
Thank you for submitting your paper.
I have questions regarding the following points, please answer them.
##JAK inhibitors are indicated and positioned for ulcerative colitis in intractable cases in which
at least one biological drug is ineffective or insufficiently effective.  In this cohort, bionaive
cases account for the majority, but are the indications and positioning of JAK inhibitors different
from international standards in South Korea? If so, please also mention the reason.
##Is there a difference in the incidence of adverse events between elderly and young people?
##Are the safety profiles and efficacy different for maintenance doses of 10 mg BID and 5 mg
BID? If the dose was changed and remission was maintained, would adverse events increase
with longer duration of 10 mg BID administration?
##Regarding herpes zoster risk management, how many patients received vaccinations? Did
the risk of developing HZ be reduced by whether or not vaccination was administered?
assistant